Our Mission
We are relentless in our pursuit of improving the lives of people impacted by neurological and endocrine disorders. We listen, and place the unique needs of patients and families at the forefront of all we do.
Spruce Bio is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need.
Spruce is developing tildacerfont as a precision treatment for major depressive disorder (MDD) in collaboration with HMNC Brain Health, leveraging its proprietary precision diagnostic tool, Cortibon, to identify patients most likely to respond to treatment. Tildacerfont has the potential to mediate responses to stress, which may be able to address up to 50% of MDD patients worldwide using Cortibon.
Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including polycystic ovary syndrome (PCOS).
